Fig. 5: Inactivation of c-MYC/SULT2B1 axis disturbs glycolytic metabolism to diminish proliferation and chemoresistance of colon cancer cells. | Cell Death & Disease

Fig. 5: Inactivation of c-MYC/SULT2B1 axis disturbs glycolytic metabolism to diminish proliferation and chemoresistance of colon cancer cells.

From: Knockdown of OLR1 weakens glycolytic metabolism to repress colon cancer cell proliferation and chemoresistance by downregulating SULT2B1 via c-MYC

Fig. 5

Colon cancer cells were treated with sh-NC + oe-NC, sh-c-MYC + oe-NC, or sh-c-MYC + oe-SULT2B1. A The mRNA expression of c-MYC and SULT2B1 in colon cancer cells tested by RT-qPCR. B Detection of ECAR in colon cancer cells. C Glucose content in colon cancer cells. D Lactate production in colon cancer cells. E The ATP/ADP in colon cancer cells. F RT-qPCR to measure the mRNA expression of GLUT1 and LDHA in colon cancer cells. G MTS to calculate the proliferation level of colon cancer cells. H Colony formation assay to check the level of colony formation in colon cancer cells. I Detection of Ki67 mRNA expression in colon cancer cells by RT-qPCR. Colon cancer cells were treated with sh-NC + oe-NC, sh-c-MYC + oe-NC, or sh-c-MYC + oe-SULT2B1, followed by treatment with DDP, oxaliplatin, 5-Fu, and paclitaxel. J The drug resistance of colon cancer cells to DDP, oxaliplatin, 5-Fu, and paclitaxel detected by MTS. K RT-qPCR for detecting the mRNA expression of P-gp and SMAD4 in colon cancer cells. The cell experiments were repeated three times. *p < 0.05 between two groups.

Back to article page